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Modern health care requires a proactive and individualized response to diseases, 
combining precision diagnosis and personalized treatment. Accordingly, the approach 
to patients with allergic diseases encompasses novel developments in the area of per-
sonalized medicine, disease phenotyping and endotyping, and the development and 
application of reliable biomarkers. A detailed clinical history and physical examination 
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1  | INTRODUC TION
Allergic diseases represent a group of conditions caused by hyper-
sensitivity of the immune system to allergens present in the environ-
ment.1 These diseases include food allergy, asthma, atopic dermatitis 
(AD), allergic rhinitis (AR), conjunctivitis and chronic rhinosinusitis 
with or without nasal polyposis (CRSwNP).2–4 The 100-year-old 
personalized allergen-specific management of allergic diseases has 
been a particular advantage in our specialty contributing to the early 
awareness of personalized approaches and precision medicine. The 
use of multiple omics, big data and systems biology has demon-
strated a profound complexity and dynamic variability and enabled 
the discovery of novel biomarkers.5
Generally, a biomarker is a measurable indicator of the presence 
and severity of diseases or their response to a treatment with clear 
cutoff points. Regarding the prediction, diagnosis or monitoring of dis-
eases, biomarkers are gaining importance in clinical practice as they 
provide an objective and measurable way to characterize a disease. 
However, it is challenging to identify convincing biomarkers as the 
genetic and regulatory networks for individual patients differ signifi-
cantly. Biomarkers represent measurable indicators linking an underly-
ing pathway to a phenotype or endotype of a disease.6–8 Regrettably, 
current biomarkers are not precise in selecting the specific endotype 
that will respond to a targeted treatment. A good example is the ob-
servation that blood eosinophilia predicts therapeutic responses to all 
currently available or future-targeted interventions in severe asthma 
(i.e, anti-IL-5, IL-4/IL-13, CRTH2 antagonists).8,9 Precision medicine in 
allergic diseases demands accurate diagnoses,10 which mostly rely on 
the combination of the clinical history and respective gold standards, 
which are all subject to the operator, observer and interpretation vari-
ability.11,12 Some of the approaches are time-consuming, and in vivo 
challenges may result in severe side-effects and, in rare cases, even 
death. Therefore, the discovery, validation and clinical applicability of 
molecular biomarkers become increasingly important.13
The cellular, biochemical or molecular changes in allergic patients 
which are measurable in blood, sputum or nasal secretions can be con-
sidered as biomarkers.14 These biomarkers are used for disease diag-
nosis, selection of targeted therapy, disease monitoring and prediction 
of prognosis.15 Except for the well-known biomarkers (e.g, IgE, blood 
or sputum eosinophilia, fractional exhaled nitric oxide [FeNO]),16–18 
research focusing on pro-inflammatory mediators, genes, the epithe-
lial barrier and microbiomes is now emerging, which highlights more 
potential biomarkers for allergic diseases.19,20 Some of the biomarkers 
showing a strong ability to identify disease endotypes or phenotypes 
may also act as therapeutic targets.21,22 This article reviews the bio-
markers identified to date and potential targeted therapies in allergy. In 
addition, it briefly reviews the biomarkers included in EAACI guidelines.
followed by the detection of IgE immunoreactivity against specific allergens still rep-
resents the state of the art. However, nowadays, further emphasis focuses on the 
optimization of diagnostic and therapeutic standards and a large number of studies 
have been investigating the biomarkers of allergic diseases, including asthma, atopic 
dermatitis, allergic rhinitis, food allergy, urticaria and anaphylaxis. Various biomarkers 
have been developed by omics technologies, some of which lead to a better classifica-
tion of distinct phenotypes or endotypes. The introduction of biologicals to clinical 
practice increases the need for biomarkers for patient selection, prediction of out-
comes and monitoring, to allow for an adequate choice of the duration of these costly 
and long-lasting therapies. Escalating healthcare costs together with questions about 
the efficacy of the current management of allergic diseases require further devel-
opment of a biomarker-driven approach. Here, we review biomarkers in diagnosis 
and treatment of asthma, atopic dermatitis, allergic rhinitis, viral infections, chronic 
rhinosinusitis, food allergy, drug hypersensitivity and allergen immunotherapy with a 
special emphasis on specific IgE, the microbiome and the epithelial barrier. In addition, 
EAACI guidelines on biologicals are discussed within the perspective of biomarkers.
K E Y W O R D S
allergen immunotherapy, allergic rhinitis, asthma phenotypes and endotypes, biomarkers, food 
allergy
Respiratory viral infections may exacerbate chronic air-
way inflammatory diseases, including allergic inflamma-
tion through both Type 2 (e.g, IL-25, IL-33 and TSLP) and 
non-Type 2 (e.g, IFN types I and III, RIP3, OSM, MCIDAS) 
mechanisms.
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2  | BIOMARKERS IN A STHMA
In the past decades, it has been increasingly recognized that asthma 
is a highly heterogeneous disorder with different underlying mecha-
nisms and pathways translating into variable responses to standard 
treatment across the different subsets or clinical phenotypes.23,24 
Unbiased approaches and cluster analyses identified four major clini-
cal phenotypes: (a) early-onset allergic asthma, (b) early-onset allergic 
moderate-to-severe asthma, (c) late-onset nonallergic eosinophilic 
asthma and (d) late-onset nonallergic noneosinophilic asthma.25 The 
late-onset subsets tend to present as more severe or more difficult 
to treat than early-onset asthma. To promote an adequate treatment 
strategy, asthma can be subdivided into Type 2 (high) and non-Type 
2 (or Type 2 low) endotypes based on their underlying inflamma-
tory pathways.26 As part of a more general syndrome often includ-
ing nasal polyps with or without NSAID-Exacerbated Respiratory 
Disease (NERD),27,28 Type 2 asthma currently comprises the best 
defined asthma subset(s) in terms of underlying immunopathology, 
corresponding biomarkers8 and targeted treatment options with 
biologicals and small molecules.13,29,30
In parallel with the available (targeted) treatment options, bio-
markers have been validated along the corresponding inflammatory 
pathways aimed for pheno-/endotyping and to guide treatment for 
Type 2 asthma.8 Clinically applicable point-of-care biomarkers in-
clude blood eosinophils, or whenever feasible, sputum eosinophil 
counts, serum-specific IgE and FeNO.8,31 Although overlapping in 
Type 2 biomarkers may occur within patients, all biomarkers repre-
sent different aspects of the Type 2 inflammatory pathways with IgE 
associating with allergy, while FeNO is linked to the IL-13 pathway 
and epithelium-derived inflammation.8 Based on these point-of-
care biomarkers in combination with clinical characteristics (age of 
onset, comorbidities, exacerbations, need for maintenance systemic 
corticosteroids) and physiological parameters (lung function, airway 
hyperresponsiveness, etc), current guidelines have now adapted al-
gorithms which can help to predict a response to (targeted) treat-
ments and/or can be used to monitor the subsequent treatment 
response.23,32,33 In this context, some confounders have been 
recognized for the existing point-of-care biomarkers, i.e, for FeNO 
mainly related to ICS use, smoking, dietary nitrate intake, virus in-
fections and bronchoconstriction, while for blood eosinophils circa-
dian variation, parasites and systemic corticosteroids were found to 
be the most common perturbing factors.23,34 In parallel with FeNO, 
oxidative stress can also be caused by an excess of reactive oxygen 
and nitrogen species. Many direct or indirect markers of oxidative 
stress such as bromotyrosine, malondialdehyde, isoprostane, thio-
barbituric acid, glutathione disulfide have been detected in urine, 
plasma, sputum and BAL fluids of patients with asthma, and the level 
of these markers correlated with the clinical output and severity of 
the disease.35–37 A noninvasive way of analysis, exhaled breath con-
densate collection, has allowed direct measurements of pH changes, 
H2O2 and the measurement of several indirect by-products of ox-
idation like 8-isoprostane and ethane.38,39 Currently, the presence 
of high levels of urinary bromotyrosine is a promising noninvasive 
biomarker of oxidative stress for clinical use in asthma patients. In 
this context, a clinically relevant issue has been raised, i.e, whether 
“true” non-Type 2 (noneosinophilic) asthma really exists among pa-
tients with severe asthma, given the fact that high-dose inhaled and 
oral corticosteroids may potentially mask preexisting Type 2 inflam-
mation interfering with its biomarkers, especially blood eosinophils 
and FeNO.40,41 Currently ongoing corticosteroid-tapering studies 
(RASP-UK) in patients with non-Type 2 severe asthma should an-
swer this question. Alternatively, airway neutrophilia (“neutrophilic 
asthma”) may often reflect (subclinical) airway infection.41–43
In contrast, for non-Type 2 asthma which is by default defined as 
asthma without Type 2 biomarkers, underlying pathways and, hence, 
clinically applicable biomarkers and targeted treatment options are 
still largely under exploration.41,44 Apart from most patients with 
mild clinically stable asthma,26,45 clinical phenotypes frequently 
associated with non-Type 2 asthma include very late-onset asthma 
(women), obesity-associated asthma, smoking-associated neutro-
philic asthma and paucigranulocytic asthma. Although generally 
based on increased sputum neutrophils or absence of normal lev-
els of (sputum) eosinophils and neutrophils (paucigranulocytic) with 
normal levels of other Type 2 markers, the diagnosis of non-Type 2 
asthma is difficult to establish as often based on cross-sectional data 
potentially affected by confounders including respiratory infections 
or anti-inflammatory therapies.41 In the absence of targeted biolog-
icals, in non-Type 2 asthma treatable traits should be targeted,46–48 
e.g, obesity, smoking habits, psychological aspects, neutrophilia as 
a potential indicator of respiratory infection and airway narrowing 
or airway hyperresponsiveness as an indicator of ASM dysfunction, 
while corticosteroids may not be effective and should be tapered 
off (Figure 1).23
In conclusion, despite substantial progress in our understand-
ing, applicable biomarkers and targeted treatment options for Type 
2 asthma, further characterization of molecular pathways by omics 
technologies,49–51 sophisticated imaging52 and innovative anatomi-
cal approaches53 should help to further unravel the complexity of 
asthma and to define reliable (composite) biomarkers and therapeu-
tic strategies for patients nonresponsive to currently available (tar-
geted) treatment options including non-Type 2 asthma.
3  | BIOMARKERS LINKED TO 
MICROBIOME AND A STHMA
An enormous variety of microbes colonize mucosal body sur-
faces, and these microbes are organized within complex com-
munity structures, utilizing nutrients from other microbes, host 
secretions and the diet. Modern lifestyles, medications and so-
cial interactions have fundamentally altered and disrupted the 
human microbiome metacommunity and, as a consequence, risk 
of immune-mediated diseases such as allergy and asthma.54,55 
The mechanisms that mediate host–microbe communication are 
highly sophisticated and are being intensely investigated by many 
research groups across the world. However, there is accumulating 
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evidence that microbiome composition and metabolic activities 
within the gut and the airways can influence asthma pathogen-
esis.56–58 Here, we summarize some of the key recent findings that 
identify specific microbes or associated metabolites that may be 
useful as biomarkers to predict asthma risk, asthma severity or 
guide existing or novel therapies.
Alterations in the gut microbiota within the first year of life have 
been associated with asthma risk in multiple birth cohort studies.19 
F I G U R E  1   Treatment based on molecular biomarkers for endotypes in asthma. Asthma can be subdivided into Type 2 (high) and non-type 
2 (or type 2 low) endotypes based on their underlying inflammatory pathways. For Type 2 high asthma, potential biomarkers could be serum-
specific IgE (sIgE), fractional exhaled nitric oxide (FeNO) and blood or sputum eosinophils, and in some more specialized centers periostin. 
Moreover, Type 2 cytokines (IL-4, IL-5 and IL-13) and innate (epithelial) cytokines (IL-25, IL-33 and TSLP) can also be important biomarkers. 
The options to treat with biologicals emphasizing biomarkers of Type 2 high endotype have entered the market: IgE (omalizumab), IL-5 
(mepolizumab, reslizumab, benralizumab) and IL-4/IL-13 (dupilumab). In contrast, the diagnosis of Type 2 low asthma is difficult to establish 
as generally based on increased sputum neutrophils or paucigranulocytic with normal levels of other Type 2 markers, and non-Type 2 
cytokines (IL-8 or IL-17). There are still some associated indicators including obesity, smoking habits and psychological aspects. Therefore, 
therapeutic strategies for patients with Type 2 low asthma could be macrolides and bronchial thermoplasty
F I G U R E  2   Microbiome Biomarkers in Asthma. Alterations in the gut and airway microbiota during childhood have been associated with 
asthma risk. The higher relative abundance of Veillonella and Prevotella and a switch from a Corynebacterium and Dolosigranulum cluster to a 
Moraxella cluster in the upper-airways were associated with a higher risk of severe asthma exacerbation in children with asthma. The lower 
relative abundance of genera including Lachnospira, Veillonella, Faecalibacterium, Rothia, Bifidobacterium and Akkermansia in the gut during 
early life has been associated with the development of asthma. The increases in relative abundance of Gemmiger, Escherichia, Candida and 
Rhodotorula within the gut were also associated with the subsequent development of asthma
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The lower relative abundance of genera including Lachnospira, 
Veillonella, Faecalibacterium, Rothia, Bifidobacterium and Akkermansia 
in the gut during early life has been associated with the develop-
ment of asthma.59,60 While fewer studies have examined pre-
school children (2-4 years of age), a recent study in this age group 
demonstrated that certain bacterial genera within the gut were still 
associated with wheezing (Collinsella and Dorea) or subsequent de-
velopment of asthma (Gemmiger and Escherichia).61 In addition to the 
gut microbiota, studies are also showing changes in the microbial 
populations of the airways. Microbial diversity and the relative abun-
dances of Veillonella and Prevotella in the airways at age 1 month 
were associated with asthma by age 6 years.62 Interestingly, higher 
relative abundance of these bacteria was associated with reduced 
TNF-α and IL-1β and increased CCL2 and CCL17 within the airways. 
A switch from a Corynebacterium and Dolosigranulum cluster in the 
upper airways to a Moraxella cluster was associated with a higher 
risk of severe asthma exacerbation in children with asthma.63 In 
adults, increased relative abundance of the phylum Proteobacteria 
(including Haemophilus, Comamonadaceae, Sphingomonadaceae, 
Nitrosomonadaceae, Oxalobacteraceae and Pseudomonadaceae) 
is often associated with asthma or with worse asthma control.64 
Microbial changes within the gut, upper and lower airways of adult 
asthma patients are magnified in obese asthma patients and in those 
with severe disease.65 Bronchoalveolar lavage levels of IL-5 and eo-
sinophils correlated with a variety of microbes within the airways. 
Of note, severe asthma negatively correlated with fecal Akkermansia 
levels and oral administration of Akkermansia to murine models sig-
nificantly reduced airway hyper-reactivity and airway inflammation 
(Figure 2).
In addition to microbiota composition, microbial metabolites may 
also be useful biomarkers in asthma. The fecal metabolome of chil-
dren at increased risk of asthma contained increased levels of pro-in-
flammatory metabolites, among which 12, 13 DiHOME was able to 
induce IL-4 production in CD4+T cells and decreased the abundance 
of Tregs.60 High levels of short-chain fatty acids (SCFAs), such as bu-
tyrate and propionate, at 1 year of age were associated with reduced 
risk of atopic sensitization and asthma by school age.66 Multiple im-
mune modulatory effects have been described in murine models for 
SCFAs, which include the promotion of Treg development and the 
inhibition of pulmonary ILC2 functions and subsequent develop-
ment of airway hyper-reactivity.67 In adults, an increased abundance 
of histamine-secreting bacteria was observed within the gut of pa-
tients with asthma, while disease severity correlated with high levels 
of the histamine-secreting microbe Morganella morganii.68 Murine 
models have demonstrated that bacterial-derived histamine within 
the gut can influence inflammatory responses within the lungs.69
In the future, the application of recent advances in metagenomic 
sequencing technologies and bioinformatics will likely lead to the 
identification of novel functional traits and metabolites within the 
gut and airway microbiome of asthma patients.70 In addition, future 
asthma studies should include the microbiome as potential biomark-
ers that predict or associate with responses to biologics, as already 
observed for Faecalibacterium, Bifidobacterium and Akkermansia that 
associate with immunotherapy responses in certain groups of cancer 
patients.71
4  | SKIN BAC TERIAL MICROBIOME A S 
CLINIC AL BIOMARKER IN ATOPIC EC ZEMA
Diagnosis of atopic eczema (AE) severity is still today a semi-
quantitative clinical score based on subjective information from 
the patients together with a doctor's subjective estimation of the 
severity of skin lesions and patient's history of itching and sleep 
loss.72,73 In the era of targeted therapy, and thus more complex 
therapy management requirements, more objective criteria are 
urgently needed. The serum thymus and activation-regulated 
chemokine (TARC) level has been reported as the most reliable 
biomarker for disease severity with strong pooled correlation co-
efficients with AD. Additional biomarkers that could prove useful 
but require additional research include serum cutaneous T-cell-
attracting chemokine (CTACK), sE-selectin, macrophage-derived 
chemokine (MDC), lactate dehydrogenase (LDH) and IL-18.74 A di-
agnostic biomarker to distinguish between the different subgroups 
of AE is still needed. AE, likewise, lacks a prognostic biomarker: 
AE75 affects 30% of children but only 5% of adults—thus, the ques-
tion remains who keeps the disease, who emerges from it and who 
embarks on the full career of an atopic individual. Skin microbiome 
dysbiosis, measured either as microbiome diversity or more relia-
bly as abundance of S aureus, was shown to correlate with both the 
AE clinical score and the expression of skin barrier molecules.76 It 
is still a matter of scientific debate whether the relative frequency 
of various bacteria (e.g, S aureus frequency as obtained from 
16S-based NGS) is an adequate biomarker or rather the absolute 
microbial load (e.g, as obtained from qPCR) is better. Furthermore, 
is it enough to quantify the DNA abundance from nonstandardized 
amounts of skin samples, or rather is the absolute microbial load of 
standardized skin samples needed?
S aureus is important for AE pathogenesis even though it is still 
a matter of debate whether overgrowth of S aureus is a cause or 
a result of barrier disruption.77 Thus, microbiome analysis, at least 
on the species level, but ideally on the strain level, would enable us 
to identify personalized biomarkers. This highlights a methodologi-
cal drawback, as currently tools for annotation on species level are 
not reliable. Furthermore, the current methods for skin microbiome 
measurement are not standardized; testing the same material in 
different laboratories is prone to give different results. For skin mi-
crobiome to be used clinically as a biomarker, standardized method-
ology needs to be developed and validated so it can be reliably used 
across different laboratories.78 Combinatory biomarkers between 
skin microbiome and biomarkers of Type 2 immunity would also be 
of great potential.79 Recently, biofilm propensity of S aureus skin iso-
lates as a cause and possible target has become more and more of a 
central issue.80 Thus, resolving the enigma of skin–microbe interac-
tion as a function of skin homeostasis has to take more players into 
the sight.81
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In conclusion, skin bacterial microbiome shows great potential 
to be used as a clinically important biomarker for atopic eczema. To 
reach this aim, we need to perform prospective clinical trials and 
large longitudinal registries that include skin microbiome testing. 
Furthermore, it is critical to advance standardized and foremost 
quantitative methodologies for skin bacterial microbiome analysis. 
New technologies, such as single-molecule real-time (SMRT) se-
quencing , need to be further developed and tested in order to im-
prove skin microbiome analysis with higher accuracy and/or longer 
sequencing length. Collaboration between large academic consortia 
and pharmaceutical companies is essential for such endeavors.
5  | BIOMARKERS IN DIAGNOSIS OF 
ALLERGIC RHINITIS
With deeper insights into mechanisms of AR, novel biomarkers have 
recently been identified in its diagnosis. Furthermore, several im-
mune cells and mediators, genes and metabolites have been studied 
to explore their potential utilization in diagnosis of AR.
5.1 | Immune cells and mediators
Several potential immune cells (granulocytes, lymphocytes, etc) and 
mediators might serve as diagnostic biomarkers of AR.14,82 Izuhara 
and colleagues have reported that induction and increased expres-
sion of periostin reflect Type 2 inflammation and remodeling and 
could be regarded as an emerging biomarker for allergic diseases.83 
One study has demonstrated that allergen-induced surface CD203c 
expression on basophils exhibits a time-of-day-dependent variation, 
and allergen-specific basophil reactivity shows daily variations de-
pending on circadian clock activity in basophils, which could partly 
be responsible for temporal symptomatic variations in AR.84 One 
recent study has suggested that circulating group 2 innate lymphoid 
cells (ILC2s) may play an important role in the pathology of AR, par-
ticularly as increased levels of ILC2s correlated with symptom scores 
and IL-13 levels in house dust mite (HDM)-sensitized AR patients,85 
and these cells produce large amounts of proinflammatory media-
tors in response to Th2 cytokines.86,87 Indeed, a more recent study 
by Tojima and colleagues found that prostaglandin D2 (PGD2) and 
cysteinyl leukotriene (cysLTs) might induce ILC2s to produce Th2 
F I G U R E  3   Immune cells and mediators as biomarkers in allergic rhinitis (AR). AR is associated with abnormalities in epithelial barrier 
function which is caused by exposure to exogenous proteases from allergens bacteria and viruses. These changes in epithelial barrier could 
contribute to the allergen absorption and disruption of epithelial tight junction. Activated dendritic cells (DCs) present allergen peptides 
to naive T cells and drive them to differentiate into Th2 cells and also allergen-specific Th2A cells. Damaged epithelial cells release a high 
level of alarmin (TSLP, IL-25, and IL-33), which activate the group 2 innate lymphoid cells (ILC2s) as well as pathogenic memory T helper 
(Th) 2 cells. All these cells produce large amounts of proinflammatory mediators including IL-4, IL-5, IL-9, and IL-13. Besides, IL-4 and IL-
13 are involved in IgE class switch in B cells. IgE binding to mast cells can trigger the release of mast cell-associated mediators, such as 
prostaglandin D2 and leukotrienes, which could also activate the function of ILC2. PGD2 signaling could be a promising biomarker, as it can 
also activate eosinophils and basophils. Moreover, CD203c expression on basophils exhibits a time-of-day-dependent variation, which could 
partly be responsible for temporal symptomatic variations in AR. IgG4 increased during allergen immunotherapy (AIT) is purported to be a 
blocking antibody by competing for allergen binding with IgE bound to Fcε receptors on mast cells and basophils. cysLT, leukotrienes; PGD2, 
prostaglandin D2 
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cytokines such as IL-5 and IL-13.88 Similarly, ST2-expressing patho-
genic memory T helper (Th) 2 cells, producing substantial amounts of 
IL-33-induced IL-5 and IL-13, have been shown to be linked to sensiti-
zation and the onset and progression of AR (Figure 3).89
5.2 | Genes
Epigenetic modifications, particularly DNA methylation and micro-
RNAs (miRNAs), might have the potential to identify AR patients. 
One recent study has demonstrated changes in DNA methylation of 
tryptase gamma 1 (TPSG1), schlafen (SLFN12) and mucin 4 (MUC4) 
genes, following controlled allergen challenge, and suggested that 
baseline epigenetic status may act as a potential biomarker for AR 
symptom severity.90 Another recent study has indicated that the 
nasal epigenome associated with asthma, FeNO and IgE may serve 
as a sensitive biomarker of asthma, allergy and airway inflammation 
in children.91 Other studies have reported that subsets of circulating 
miRNAs are solely expressed in the blood of patients with AR and 
asthmatics and may therefore be used as noninvasive biomarkers for 
diagnosis and characterization of these diseases.92,93
5.3 | Metabolites
Metabolites have also been proposed as biomarkers for AR. A 
very recent study of serum metabolomics has demonstrated that 
at least nine metabolites (13(S)-HPODE, bilirubin, leukotriene D4, 
hypoxanthine, L-stercobilinogen, N-succinyl-L-diaminopimelic acid, 
chlorophyll b, 15-hydroxyeicosatetraenoic acid and urate) were 
significantly altered in the serum of AR patients and therefore may 
provide a better understanding of the metabolic pathways involved 
in the etiology of AR.94 Additionally, a decreased serum lactofer-
rin level has been reported to be associated with the phenotype of 
Dermatophagoides pteronyssinus (Der p 1)-sensitive AR and, in com-
bination with serum Der p 1-specific IgE levels, may serve as a sero-
logic biomarker for early detection of AR.95
5.4 | Clinical biomarkers of allergic rhinitis
Clinically, rhinitis phenotypes include nonallergic rhinitis (NAR), AR, 
local allergic rhinitis (LAR) with a localized allergic response but no 
systemic atopy. In some cases, basic SPT and an sIgE test are not 
efficient to discriminate between these phenotypes. Recently, a 
retrospective study was conducted to investigate the safety and 
reproducibility of the nasal allergen challenge (NAC) carried out 
over 12 years in Spain. It was shown that 99.97% NACs were well 
tolerated without delayed, local severe or systemic adverse events 
in allergic patients for both children and adults. Moreover, there 
were no significant differences in three consecutive NAC with a 
single allergen per session (NAC-S) proving the reproducibility of 
NACs.96 Regarding the monitoring of the NAC, it was shown that the 
%Vol2-6 cm by acoustic rhinometry (AcRh) displayed an optimal dis-
criminative power for AR patients from both NAR and HC subjects.97
Although the nasal provocation test (NPT) is considered a key 
tool to diagnose LAR, it requires well-trained personnel and is 
time-consuming. In this regard, the basophil activation test (BAT) 
should be helpful for supporting the diagnosis of LAR. BAT shows 
50%-66.6% sensitivity and 90%-100% specificity of LAR, which is 
more sensitive than an sIgE test and less time-consuming than NACs 
as an in vitro test.98–100 There is a new AR phenotype named dual 
allergic rhinitis (DAR), where patients show SPT positivity to sea-
sonal allergens only, but suffer from perennial symptoms and react 
to both perennial and seasonal allergens. For these patients, BAT 
displays 100% positivity with seasonal allergens and 60% positivity 
with perennial allergens.101
Overall, NAC can act as a gold standard in distinguishing the AR 
phenotype. And BAT could also be useful as an in vitro tool for LAR/
DAR diagnosis in the daily practice.
5.5 | Biomarkers in therapy of allergic rhinitis
Currently, optional therapeutic measures for AR involve patient 
education, environmental control, pharmacotherapy, allergen immu-
notherapy (AIT) and surgery.102,103 Traditional medications include 
nasal corticosteroids, antihistamines, mast cell stabilizers, decon-
gestants, etc MP29-02, a combination of nasal corticosteroid and 
antihistamine, is a novel topical medication which has proved to be 
effective in reducing nasal hyperreactivity and nasal mediators such 
as substance P, in patients with AR.104 As ILC2s have been shown 
to produce significant amounts of proinflammatory mediators in re-
sponse to epithelium-derived cytokines86,87 and PGD2 and cysLTs88 
in AR patients, agents targeting the ILC2s and the mediators acti-
vating these cells have become targets for therapy. Rittchen and 
Heinemann have recently reviewed the central role of hematopoi-
etic PGD2 synthase in allergic inflammation and indicated that PGD2 
signaling might be a promising therapeutic target for AR, as PGD2 
can activate Th2 cells, eosinophils and basophils.105 Indeed, a ran-
domized controlled phase II clinical trial has recently demonstrated 
that ONO-4053, a novel prostaglandin D receptor 1 antagonist, was 
more effective than pranlukast, a leukotriene receptor antagonist, in 
treating patients with seasonal AR.106 Most recently, emerging stud-
ies have focused on biologics for treating allergic diseases; especially 
severe, uncontrolled asthma and AD, as well as AR.107,108 To date, 
a high number of specific biologics targeting markers of Th1/2/17 
inflammation have been introduced; with more underdevelop-
ment.107,109 In particular, targeting IgE by omalizumab, a recombi-
nant humanized anti-IgE antibody, has been shown to significantly 
improve symptoms in patients with inadequately controlled AR.110 
Furthermore, combining omalizumab with subcutaneous immune 
therapy (SCIT) in patients with SAR and comorbid seasonal allergic 
asthma has been shown to lead to greater clinical improvements in 
AR and lung function than SCIT alone.111 Similarly, dupilumab, a bio-
logic which targets IL-4Rα to block the activity of both IL-4 and IL-13, 
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has been shown to provide nasal symptom relief in patients with un-
controlled asthma and comorbid AR.112
6  | BIOMARKERS OF VIR AL INFEC TIONS 
IN E X ACERBATION OF ALLERGIC RHINITIS 
AND A STHMA
Over the past decade, our understanding of immunological mechanisms 
underlying allergic diseases such as AR has substantially increased 
through the discovery of T helper (Th) subsets and their importance in 
allergic inflammation. Emerging data now provide new insights on the 
Type 2 immune response that is an immune response to allergens and 
involves Th2 cells, Type 2 B cells, ILC2s, Type 2 macrophages, a small 
fraction of IL-4-secreting NK cells, IL-4-secreting NK-T cells, basophils, 
eosinophils and mast cells.113 At the same time, it has also been estab-
lished that viral infection synergizes with allergic inflammation causing 
more severe exacerbations and symptoms compared to both condi-
tions alone.114,115 There are increasing evidences that most respiratory 
viral infections could trigger or exacerbate chronic Type 2 inflamma-
tory responses via excessive release of chemokines and cytokines into 
the airways.116–118 While much of these studies focus on lower airway 
inflammatory diseases instead of AR, insights from these studies can 
be applied to ongoing studies of virus-induced AR exacerbations and 
the search for its associated markers.
Like other chronic airway inflammatory diseases, AR patients also 
suffer from altered responses and potentially increased susceptibil-
ity toward viral infection.119–121 This is similarly due to the reduced 
Type 3 interferon response, which is crucial against incoming viral in-
fection in the upper airway.119–121 Hence, markers for virus-induced 
AR exacerbation may have a significant overlap with findings from 
other inflammatory airway diseases. Proinflammatory cytokines 
such as TNF-α, IL-4, IL-5, IL-13, RANTES, Eotaxin, TSLP, IL-25 and 
IL-33 are usually expressed at higher concentrations in chronically 
inflamed airways, some of which are also found in AR.113,122,123 
These cytokines can be further triggered directly or indirectly by 
virus-induced IFNs, cytokines and chemokines. Infections such as 
RSV can even further shunt antiviral responses toward a more Type 
2-centric response.124–128 In addition, the discovery of ILC2s, a group 
of lymphoid cells, further emphasized the role of epithelial alarmins 
IL-25, IL-33 and TSLP in viral-induced exacerbation.129 During viral 
infection, these three cytokines were secreted in response to ep-
ithelial injury.130–132 It has been reported that IL-5, IL-13 and IL-33 
levels were elevated in both the BAL and nasal fluid of asthmatics 
after RV16 infection compared to healthy subjects. The nasal IL-33 
level was significantly and positively correlated with the total lower 
respiratory symptom score. Moreover, IL-33 secreted by RV-infected 
BECs directly induced IL-5 and IL-13 production by human blood 
ILC2s.133 Together, it indicated that activated ILC2s in the upper and 
lower airways could cooperate to aggravate a Type 2 inflammation 
resulting in acute viral exacerbation. However, there are higher ILC2 
levels in the blood of allergic asthmatics compared to patients with 
allergic rhinitis and even higher levels in patients with combined 
asthma and AR.87,134 Furthermore, ILC2s from allergic asthmatics 
were more responsive to IL-33 and IL-2 treatment compared to pa-
tients with allergic rhinitis.134 These differences may cause the di-
verse severity of allergic airway diseases (Figure 4).
In addition, respiratory viral infections may also exacerbate 
chronic airway inflammatory diseases, including allergic inflam-
mation through other non-Type 2 mechanisms, in which other 
markers can also be used as an indicator of these exacerbations. 
Viral infections can lead to the destruction of epithelial barrier 
and disruption of mucociliary function due in part to cell death in 
the virus-infected epithelium. Hence, markers for cell death (e.g, 
RIP3) and mucociliary dysfunction (e.g, MCIDAS) constitute part 
of the viral exacerbation repertoire.124 Viral infection also causes 
increase in factors such as OSM and ANGPTL4 which disrupts 
tight junctions leading to increased allergen invasion and their 
contact with immune cells in the sub-epithelium region, thereby 
exacerbating allergic symptoms.135,136 In addition, miRNAs are 
increasingly implicated in the mis-regulation of inflammatory re-
sponses and several of them are found to be dysregulated in an 
inflamed airway. For example, expressional changes of miRNAs 
such as miR-21 may coincide with viral infection responses and 
hence linked to virus-induced exacerbations.137 Finally, an emerg-
ing field of bioenergetics and mitochondrial function may also 
contribute to the mechanism of virus-induced exacerbation in 
AR. Oxidative stress and mitochondrial dysfunction from viral in-
fection may induce increased inflammation, and thus ROS and its 
associated markers may potentially serve as key markers for viral 
exacerbation.138,139
7  | BIOMARKERS IN CHRONIC 
RHINOSINUSITIS
CRS can be divided into different pheno- and endotypes. The mostly 
used phenotype is the division into CRS with and without nasal pol-
yps (CRSwNP and CRSsNP), although many other pheno- and endo-
types are known.28,140 However, recently, the options to treat with 
biologicals have put more emphasis on markers of Th2 disease irre-
spective of the presence of nasal polyps. The first Type 2 targeting 
biologic anti-IL4Rα (Dupilumab) has entered the market for CRSwNP 
patients, and others like anti-IgE, anti-IL5 and anti-IL5Rα may fol-
low shortly.141–143 Cluster analysis of CRS has shown that CRSsNP 
and CRSwNP are not dichotomous but instead have overlapping in-
flammatory signatures with Type 2 inflammation as the predominant 
endotype mainly in CRSwNP but also CRSsNP, especially in western 
parts of the world. Interestingly, some patients with CRS express 
a mixture of two or more inflammatory endotypes.22,144,145 The re-
cently published EPOS2020 proposes a new clinical classification 
based on the disease being localized (often unilateral) or diffuse (al-
ways bilateral). Both these groups can be further divided into Th2 or 
non-Th2 disease.4
In the very near future, it may be possible to offer personalized 
medicine for CRS patients where treatment is based on molecular 
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biomarkers for the endotype or subendotype activated in an individual 
patient.27,146 The major challenge is to find reliable biomarkers that de-
fine Th2 inflammation and predict reaction to treatment. Ideally, these 
biomarkers should be supported by a body of evidence clarifying the 
biological significance, be quantifiable in a cost-efficient way and be 
easily measurable, preferably in blood or nasal secretion.14 Potential 
biomarkers could be eosinophils, neutrophils,147,148 IgE,149Th2 cyto-
kines,150 innate (epithelial) cytokines,123,149,151 but also phenotypical 
phenomena like smell loss,152 asthma and response to systemic cortico-
steroids.146 Contrary to FeNO in asthma, nasal NO has not been shown 
to be helpful to identify the T2 endotype because the main source of 
production of nasal NO is the sinuses that are closed off when CRS 
occurs.153 The main biomarkers used at the moment to define Th2 dis-
ease are eosinophils, IgE levels and in some more specialized centers 
periostin and/or IL-5. There is quite some evidence showing that tissue 
and blood eosinophils are a reasonable surrogate marker for Th2 dis-
ease and that blood eosinophils are a reasonable biomarker to predict 
eosinophilic CRS with or without nasal polyps.145 On the other hand, 
a lack of tissue eosinophilia, lower serum eosinophilia and absence of 
tissue squamous metaplasia may predict a CRS phenotype suitable for 
a trial of long-term macrolide therapy when surgery and topical ther-
apy have failed.154 Unfortunately, recent large studies with monoclonal 
antibodies directed to Type 2 endotypes have not found reliable bio-
markers to predict response to treatment.141,142,155–157 As in asthma,8 
we need large, maybe real-life studies to find better predictors to iden-
tify responders to biological treatments. For now, our treatment de-
cisions still heavily rely on phenotypical characteristics such as smell 
loss, asthma and response to surgery and systemic corticosteroids.4,27
F I G U R E  4   Biomarkers of viral infections in the exacerbation of AR. After the epithelial cells are infected with viruses, the replicating 
virus can cause cell lysis and direct damage to the epithelium, which causes deficiency in the production of antiviral interferon (IFN)-β 
and IFN-λ1. Together with the allergen-induced cytokines IL-25, IL-33 and TSLP, ILC2s are activated and produce more Type 2 cytokines. 
Subepithelial plasmacytoid dendritic cells (pDCs) recognize virus antigens and present them to CD4+ T cells and CD8+ T cells through 
MHC class Ⅱ or Ⅰ and drive them toward a more Type 2 centric response. Excessive release of chemokines and cytokines can be triggered 
by infections such as respiratory–syncytial virus (RSV). Together with Type 2 cytokines, they could further promote the function of Type 
2 macrophages, a small fraction of IL-4-secreting NK cells, IL-4-secreting NK-T cells, neutrophils, eosinophils and mast cells and augment 
Type 2 responses in chronically inflamed airways. With the production of perforin and granzymes, CD8+ T cells can show cytotoxicity to 
virus-infected epithelial cells and induce apoptosis. The viral RNA is released and detected by airway smooth muscle cells and stimulates the 
production of prostaglandins (PGs) in an autocrine manner 
3048  |     BREITENEDER ET al.
8  | BIOMARKERS IN FOOD ALLERGY
Apart from clinical determinants of food allergy and the respective gold 
standard, the oral food challenge, biomarkers represent an area of ex-
tensive research. In food allergy, the focus is on genetic risk factors, al-
lergen-specific and nonspecific humoral and cellular biomarkers.158–160
Although genetic markers for food allergy are not yet at the level 
of clinical relevance, genes linked to HLA-genes, and more impor-
tantly to epithelial integrity and consequently reduced barrier func-
tion like filaggrin, SPINK5161 and SERPINB7, are linked to eczema 
development and also food allergy.162–168 Given the importance of 
the exposome in allergy development, epigenetics may even play a 
more important role. Promising results in the context of peanut al-
lergy await replication in larger cohorts.169,170 Regulation at another 
level has been linked to the microRNA 193a-5p. It is involved in the 
posttranscriptional regulation of IL-4 and downregulated in PBMCs 
from milk allergic children.171 Due to the importance of barrier (dys)
function in atopic diseases,172–174 measurement of skin integrity may 
be a very important tool to identify high-risk populations. Electrical 
impedance spectroscopy, successfully tested in rodents, may be ca-
pable of assessing this biomarker also in humans.175
Allergen extract-based testing methodologies like skin prick 
test (SPT) and/or specific IgE (sIgE) tend to be less efficient for the 
diagnosis of food allergy. Thus, more specific approaches focusing 
on specific allergens (see section on allergens) and epitope-specific 
antibody response patterns are explored.176 Diversity of IgE binding 
to linear epitopes correlated with the severity of peanut and milk 
allergy,177–179 and IgG4 and IgE antibody binding to specific milk 
epitopes was stronger and more diverse in children who do not 
outgrow their milk allergy.178 By measuring IgE and IgG4 responses 
with bead-immobilized milk epitopes and applying machine learning 
approaches, nonreactivity to baked milk could be predicted twice 
as successful as by conventional approaches.180–182 The soluble 
high-affinity IgE receptor (FcεRI) may also act as a biomarker for IgE-
mediated pathologies in a less allergen-independent way.183
Although allergen-specific T-cells are extremely rare, they dis-
play a pronounced Th2 type in allergic individuals.184,185 A subset 
of allergen-specific memory Th2 cells called TH2a cells, which are 
CD45+CD27−CD45RB−CRTH2+CD161+CD49+, has been discovered. 
They are almost exclusively found in allergic individuals, secrete IL-5 and 
IL-9, and within that group, the percentage of Type 2 cytokine double, tri-
ple, or quadruple positive cells is higher compared to Th2 cells. Moreover, 
mRNA expression of IL-25, IL-33 and TSLP receptors is higher.186
Our understanding of B-cell regulation has significantly evolved 
over the last few years.187 Evidence is pointing toward an extreme 
rarity of IgE memory B-cells in peripheral blood of allergic individuals, 
which may be absent in nonpeanut allergic individuals.188 New thera-
peutic and diagnostic options opened up from data on allergen-specific 
monoclonal antibodies that were generated via single-cell sorting of 
allergen-specific memory B-cells.189,190 B-cell IgE antibody mutational 
maturation has been associated with barrier dysfunction.191 Recently, 
the co-emergence of short-lived IgE plasmablasts and IgG memory 
B-cells early in grass AIT in the absence of memory IgE + B-cells has 
been reported.192,193 Both subsets shared clonotypes supporting the 
existence of pools of specific B-cell subsets, e.g, from IgG1-positive 
allergen-specific B-cells upon switch factors and stimulation as 
demonstrated in mice.192,194 Yet many questions on the emergence of 
IgE-producing cells and their regulation have to be answered, and new 
biomarkers in this context will arise.
Functional tests that simulate allergen exposure in vitro like the 
basophil activation test (BAT) offer the possibility to assess aller-
gen-induced IgE cross-linking. The BAT suggests adding significant 
diagnostic value to IgE-based test methods.195–197 Promising results 
on the usage of passive sensitization strategies, mast cell lines198 or 
precursors199 have been reported.
There is still a significant need to develop biomarkers to diag-
nose and predict anaphylaxis to prevent near fatalities and fatali-
ties.200,201 Beyond tryptase, which can be a very good marker in the 
emergency setting when baseline values exist,82,202 predictors of 
life-threatening reactions which can be measured on a routine basis 
or in multicenter trials are still missing.
There is the hope that the expanding array of novel mechanistic 
and diagnostic biomarkers provide the toolkit to develop algorithms 
or machine learning approaches to diagnose food allergy and predict 
treatment outcomes (Figure 5).
9  | sIGE A S BIOMARKER IN DIAGNOSIS 
OF FOOD ALLERGY
Accurate diagnoses are essential for the management of food al-
lergy.159 They depend on a detailed clinical history, objective 
markers of sensitization and double-blind placebo-controlled food 
challenges (DBPCFC).203 These are time-consuming and require spe-
cialized medical facilities, and side-effects may occur. Consequently, 
molecular allergy diagnosis aims to reveal significant associations 
between sIgE and clinical phenotypes.
9.1 | Peanut
A retrospective study of 205 peanut-challenged Danish patients 
found the best correlation between sIgE and clinical thresholds for 
the 2S albumin Ara h 2.204 A diagnostic model for peanut allergy 
predicted the food challenge outcome with 100% accuracy in 59% 
versus Ara h 2 in 50% of 100 Danish peanut-allergic patients.205 Co-
sensitization to Ara h 2 and 6 was associated with severe allergy in 
peanut-challenged Finnish patients.206 A French study of 48 peanut-
allergic children found that Ara h 2 sIgE titers could predict the risk 
of anaphylaxis.207
9.2 | Soy
The cupins Gly m 5 and 6 were suggested as markers for se-
vere allergic reactions in 30 soy-allergic European patients.208 A 
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high diagnostic value of the 2S albumin Gly m 8 was reported 
in soybean-sensitized Japanese children with and without symp-
toms.209 Gly m 8 had an AUC = 0.75 for soy allergy, while the 
values for Gly m 5 and 6 were 0.69 and 0.64, respectively. In a 
study on soy allergy diagnostics, Gly m 8 had the highest AUC 
(0.79), comparable to skin prick test (0.76) and sIgE to soy extract 
(0.77).210 In this study, the cupins Gly m 5 and 6 were related to 
mild symptoms.
9.3 | Hazelnut
sIgE to the cupin Cor a 9 and the 2S albumin Cor a 14 was strongly 
associated with clinical symptoms in 161 Dutch hazelnut-sensitized 
patients.211 sIgE to Cor a 9 and 14 allowed correct diagnosis of 90% 
of severely hazelnut-allergic Belgian children.212 In 423 hazelnut-al-
lergic patients, Cor a 9 and 14 were associated with severe symptoms 
(AUC = 0.70).213 A model combining clinical symptoms and sIgE to Cor 
a 14 and walnut increased the AUC to 0.91. In a prospective multicenter 
study of 90 peanut- and 44 hazelnut-allergic German children, a 90% 
probability for a positive food challenge was calculated for Ara h 2-spe-
cific IgE at 14.4 kU/L and for Cor a 14-specific IgE at 47.8 kU/L.214
9.4 | Walnut
sIgE to the 2S albumin Jug r 1, the cupin Jug r 2 and the nsLTP1 
Jug r 3 (AUC = 0.79, 0.70, 0.62, resp.) predicted anaphylaxis in 45 
F I G U R E  5   Biomarkers in food allergy diagnosis and treatment outcomes prediction. Conventional clinical approaches to diagnose food 
allergy include family history, skin integrity and the oral food challenge. Nowadays, expanded approaches focusing on genetic risk factors, 
allergen-specific and nonspecific humoral and cellular biomarkers were explored. Genome, epigenome and mRNA linked to epithelial integrity 
and barrier (dys)function are linked to the development of food allergy. The measurement of IgE and IgG4 binding to linear or conformational 
epitopes could be more powerful to diagnose food allergy than conventional approaches. The soluble high-affinity IgE receptor (FcεRI) may also 
act as a biomarker for IgE-mediated pathologies in a less allergen-independent way. Moreover, allergen-specific Th2A cells and memory B cells 
have been discovered as new cellular biomarkers. Functional tests that simulate allergen exposure in vitro or ex vivo like the basophil activation 
test (BAT) and mast cell activation test (MAT) offer the possibility to assess allergen-induced IgE cross-linking
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walnut-allergic children.215 In 91 walnut-allergic subjects from 
Switzerland, Germany and Spain, severe reactions correlated with 
higher sIgE levels to Jug r 1 and the cupin Jug r 4.216 sIgE to Jug r 
1 (AUC = 0.79) from 32 walnut-allergic Korean children better dis-
criminated clinical walnut allergy from tolerance than sIgE to walnut 
extract (AUC = 0.56).217 In 34 peanut-, hazelnut- or walnut-allergic 
Italian children, sIgE to Ara h 1 and Ara h 2, Cor a 9 and particularly 
Cor a 14 or Jug r 1, 2 and 3 was associated with anaphylaxis.218
9.5 | Cashew
In 63 cashew-allergic Greek children, sIgE to the 2S albumin Ana o 3 
(AUC = 0.97) performed better than extracts for predicting cashew 
allergy.219 A markedly greater risk of a positive food challenge was 
observed for higher levels of sIgE to the cupins Ana o 1 and 2, and to 
Ana o 3 in 173 Dutch children with suspected cashew nut allergy.220 
Ana o 3 discriminated between allergic and tolerant children better 
than extract-specific IgE with an AUC = 0.94 versus 0.78. A 95% 
probability for a positive cashew challenge was estimated for Ana o 
3-sIgE at 2.0 kU/L.221
9.6 | Egg and shrimp
sIgE to the ovomucoid Gal d 1 correlated with an increased risk of 
persistent egg allergy.222 Sensitization to tropomyosin and sarco-
plasmic calcium-binding protein was associated with clinical reactiv-
ity in 58 shrimp-allergic patients.223
9.7 | Cow's milk
Caseins (Bos d 8), the major protein fraction of cow's milk (80%), com-
prise four different proteins, αS1-casein (Bos d 9, 32%), αS2-casein 
(Bos d 10, 10%), β-casein (Bos d 11, 28%) and κ-casein (Bos d 12, 
10%). α-lactalbumins (Bos d 4) and β-lactoglobulins (Bos d 5) make up 
the whey proteins in cow's milk.224 An Italian study including 79 chil-
dren found that Bos d 8 could differentiate children at risk for cow's 
milk anaphylaxis (AUC = 0.718) compared to Bos d 4 (AUC = 0.491) 
and Bos d 5 (AUC = 0.634). The levels of Bos d 8 sIgE reflected the 
severity of the milk allergy.225 Additionally, low or undetectable lev-
els of Bos d 8-sIgE indicated tolerance to baked milk products.226
In conclusion, severe reactions to legume seeds and tree nuts 
are predominantly caused by sensitization to storage proteins rather 
than by pollen-related allergens such as Bet v 1 or profilin homo-
logues, or nsLTPs (Table 1).
However, biomarkers for food allergy are also affected by geo-
graphical variations and can be age-related. In Mediterranean pedi-
atric patients, Ara h 6 and Ara h 2 are the best predictors of peanut 
allergy with the prevalence of 64% and 63%, respectively.227 In 
birch-endemic regions, preschool and school-aged children with 
systemic reactions to hazelnut are mostly sensitized to Cor a 9. 
However, adults in these regions are highly sensitized to Cor a 1.04. 
Therefore, it is important to take regional and age variations into 
account when working on sIgE for food allergy.228
10  | BIOMARKERS IN DRUG 
HYPERSENSITIVIT Y
Drug hypersensitivity reactions include those mediated by a specific 
immunological mechanism and those nonspecific immune mediated 
(Figure 6).229
10.1 | Immunologically mediated specific reactions
These reactions are classified into immediate reactions (IR) and non-
immediate reactions (NIRs) depending on whether they occur within 
TA B L E  1   Specific IgE to these allergens is associated with severe symptoms
Allergen source 2S albumin
Cupin
*vicilin type
**legumin type nsLTP1 Ovomucoid Tropomyosin Caseins References
Peanut Ara h 2
Ara h 6
Ara h 1* 204–207,218
Soy Gly m 8 Gly m 5*
Gly m 6**
208–210
Hazelnut Cora 14 Cor a 9** 211–214,218
Walnut Jug r 1 Jug r 2*
Jug r 4**
Jug r 3 215,216,218
Cashew Ana o 3 Ana o 1*
Ana o 2**
219–221
Egg Gal d 1 222
Shrimp Lit v 4 223
Cow's milk Bos d 8 225
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1-6 hours or later after the drug intake. The first group is mostly 
associated with an IgE-mediated mechanism and the latter with a 
T-cell-dependent type.229,230
Skin tests (STs) are useful biomarkers for IRs to beta-lactam 
(BL).14,229–232However, their sensitivity based on the classical anti-
genic determinants has decreased over the last decades 233 possi-
bly due to the changing patterns of consumption (e.g, amoxicillin/
clavulanic acid is replacing penicillin).231 Interestingly, one antigenic 
determinant recognized by most patients with confirmed reactions 
to clavulanic acid has been recently identified.234 Therefore, amox-
icillin and any suspected BL must be included when performing 
STs.230,233,235,236 For other drugs and for NIRs, the value of STs is 
very limited.14,230,231,237
Regarding in vitro tests, during the acute phase of the reaction, 
serum tryptase is the most valuable biomarker for confirming mast 
cell activation in IR.229 The expression of granzyme B and granulysin 
in blood cells may be useful for detecting lymphocyte activation 
in severe NIR.238 At the resolution phase, immunoassays are used 
in IRs to determine sIgE, although the sensitivity is lower than for 
STs229,239,240 and only commercially available for limited drugs. For 
BLs, it shows a variable sensitivity (0%-50%),229,230,239 with the pos-
sibility of inducing false-positive results when testing for Penicillin 
V.241 The value of BAT in IR has been proven for BL and quinolones, 
giving a sensitivity up to 55%242,243 and 83%,237,244 respectively. The 
sensitivity of both sIgE and BAT correlates with severity reaction,239 
decreases with time,243,245 and depends on the activation basophil 
marker assessed, e.g, the detection of CD203c increases BAT sensi-
tivity although remaining low (36.4%).244,246
The value of lymphocyte transformation test (LTT) in NIRs has 
shown to be unsatisfactory.14,229 The Tim3/galectin-9 axis functions 
F I G U R E  6   Mechanisms of immune-mediated reactions to drugs. These reactions encompass immediate reactions (mediated by IgE) and 
nonimmediate reactions (mediated by T cells). In immediate reactions, drug-induced polarization of Th2 cells from Th0 cells promotes B cells 
to produce specific IgE (sIgE). This sIgE binds to the FcεRI receptor on mast cells. In subsequent drug contacts, the simultaneous recognition 
by at least two sIgE initiates the degranulation and release of mediators. Nonimmediate reactions are generally characterized by a Th1 
response with the increased secretion of IFN-γ from Th1 cells and granulysin from NK cells
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as a checkpoint inhibitor for Th1 cells. Interestingly, Th1 cells and 
dendritic cells of patients with drug-induced maculopapular exan-
thema expressed lower levels of Tim3/galectin-9 at baseline com-
pared with tolerant individuals.247 This observation might help 
identify subjects at risk of NIRs.
10.2 | Immunologically 
mediated nonspecific reactions
The most important group in this type of reactions is cross-intoler-
ance to NSAIDs (CI),248,249 in which patients react to NSAIDs from 
different pharmacological groups related to its COX-1 inhibitory 
activity.229,248 CI has been classically divided into phenotypes with 
exclusive skin involvement (NSAIDs-exacerbated cutaneous disease 
(NECD) and NSAIDs-induced urticarial angioedema (NIUA)) or with 
exclusive respiratory involvement (NSAIDs-exacerbated respiratory 
disease, NERD).28 Nevertheless, novel data indicate that almost 30% 
of patients with CI can experience blended reactions, especially in-
volving skin and airways.250 Genetic predisposition might account 
for the burden of some CI phenotypes (e.g, variants of GNAI2 in 
NIUA) (Figure 7).251
As the underlying mechanism is related to arachidonic acid me-
tabolism, potential biomarkers focus on determining leukotriene and 
F I G U R E  7   Mechanisms of cross-reactive hypersensitivity reactions to NSAIDs. NSAIDs induce reactions relying on their COX-1 
inhibitory activity, i.e, activation of mast cells and other immune cells without involvement of adaptive immunity. During NSAID-exacerbated 
respiratory disease (NERD), the administration of NSAIDs permits strong 5-lipoxygenase (5LOX) activation and further generation of 
leukotriene E4 (LTE4). LTE4 induces the release of IL-33 and TSLP, and consequent mast-cell activation, with bronchoconstriction occurring 
as a result of the direct effects of leukotriene C4 (LTC4), prostaglandin D2 (PGD2) and other mast cell-derived products. PGD2 recruits 
effector cells such as Th2 cells, group 2 innate cells (ILC2s), basophils and eosinophils to the airway. Consistently, in NSAIDs-exacerbated 
cutaneous disease (NECD) and NSAIDs-induced urticarial angioedema (NIUA), increased PGD2 can act on the skin epidermis. In addition, 
cross-reactive hypersensitivity to NSAIDs may involve additional sources of inflammatory mediators, such as eosinophils and platelets. ILC2: 
innate lymphoid cells 2; LTE4/C4: leukotriene E4/C4; NSAID: nonsteroidal anti-inflammatory drugs; PGD2: prostaglandin D2; TSLP: thymic 
stromal lymphopoietin; and 5LOX: 5-lipooxygenase 
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prostaglandin metabolites. Therefore, urinary LTE4 has been reported 
as a useful biomarker to distinguish between different subphenotypes 
in NERD,252 between NERD and aspirin-tolerant asthma252 and phe-
notypes with skin involvement (NIUA and NECD).21 Sensitivity and 
specificity of urinary LTE4 for identifying NERD have been reported to 
range from 0.55 to 0.81 and 0.77 to 0.82, respectively, which depends 
on the detection method used.253 Serum LTE4 and LTE4/PGF2 ratio 
have also been reported as potential in vitro biomarkers for NERD254 
and urinary PGF2 for NIUA and NECD (Table 2).21
11  | BIOMARKERS IN IMMUNE 
MONITORING OF ALLERGEN-SPECIFIC 
IMMUNOTHER APY
Allergen immunotherapy (AIT) is the only therapy that can alter the 
natural course of immune responses to specific allergens, directing 
it toward desensitization and perhaps, toward tolerance. Routes of 
AIT include subcutaneous (SCIT), sublingual (SLIT), oral (OIT) or epi-
cutaneous (EPIT).255,256 Licensed products are available for therapy 
of AR, allergic asthma, stinging insect hypersensitivity, AD.257–262 
AIT for food allergy is currently investigational; however, phase 3 tri-
als are promising.263 Current evidence indicates that immunological 
changes associated with AIT differ from permanent tolerance as in 
healthy nonallergic individuals. AIT-acquired desensitization is often 
temporary, waning with time, but can be maintained with regular ex-
posure to the allergen.256
Biomarkers that can identify responders, monitor treatment, 
predict durability of desensitization and determine adverse event 
risk would aid clinical decisions and delivery of targeted and effec-
tive treatment. With the advent of data-driven “-omic” technologies, 
more potential biomarkers have been identified.264 Here, we briefly 
review the more promising candidates that are being evaluated for 
immune monitoring with an expanded number in Figure 8.265
11.1 | Specific IgE and IgG
With the discovery of IgE in the 1960s, measurements of IgE have 
been a first step in diagnosis for atopic diseases. Both allergen-specific 
IgE (sIgE) and total IgE levels increase during the initial stages of AIT 
and subsequently decrease266; however, decreases may not accom-
pany a positive clinical outcome.267 Numerous studies indicate IgG1 
and IgG4 levels increase with therapy but do not always differenti-
ate between responders and nonresponders. IgG4 increases during 
AIT may reflect compliance not clinical efficacy.267 sIgG4 is purported 
to be a blocking antibody by competing for allergen binding with IgE 
bound to Fcε receptors on mast cells and basophils, preventing de-
granulation. IgA and other subclasses of IgG may have similar block-
ing function.268 Recent data support skewing toward IgG2 and IgG4 
subclasses after SLIT for temperate grass pollen.193 The IgG4/IgE 
ratio may monitor AIT progress and outcome, but has demonstrated 
conflicting utility.269–271 Flow cytometry-based assay (IgE-FAB) and a 
solid-phase assay enzyme-linked immunosorbent-facilitated antigen 
binding (ELIFAB) assay can determine IgE-inhibitory activity. Although 
robust with good clinical efficacy correlation for AIT, these technolo-
gies are complex with usage limited to specialized centers.267,272,273
11.2 | Immunophenotyping of immune cells
Allergic sensitization is associated with multiple changes in blood im-
mune cells,187 and high-dimensional immunophenotyping using flow 
and mass spectrometry (i.e, Cytometry Time of Flight; CyTOF) has 
contributed greatly to this identification.274 A study on bee venom AIT 
provided detailed characterization of allergen-specific B cells before 
and after bee venom tolerance in allergic patients and bee-keepers 
with Api m 1-specific B cells showing increased CCR5 expression after 
high-dose allergen exposure.275 In a study of OIT for milk allergy, re-
searchers found, using flow cytometry, a significant increase in blood 
invariant natural killer cells and a shift from a Type 2 T helper (Th-2; 
i.e, IL-4, IL-13) to a Th-1 (ie, IFN-γ) cytokine profile.276 Similar studies 
in other immunotherapy models can assist with determining potential 
biomarkers for monitoring AIT.
Recent evidence shows that AIT modulates the balance between 
circulating T follicular helper (Tfh) and regulatory cells (Tfr), with Tfr 
as a potential biomarker for AIT efficacy.277,278 Upregulation of the 
activated allergen-specific Tregs and downregulation of dysfunc-
tional allergen-specific Treg cell subset, associated with improved 
clinical response, were recently described.279 Responder status was 
shown to be associated with increased frequency of IgA- and IgG4-
expressing allergen-specific B cells, plasmablasts and IL-10+ and/or 
IL-1RA + Breg cells.280
AIT-induced T regulatory cells secreting IL-35 (iTR35) cells pro-
mote production of IL-10 from CD19 + B cells, Breg subsets and Tfr 
cells.281 Circulating Tfr cells share properties of memory cells and are 
TA B L E  2   Biomarkers for drug hypersensitivity
Biomarker Disease References
LTE4 Aspirin sensitivity in asthma 253,254
LTE4/PGF2 ratio Aspirin sensitivity in asthma 254
LTE4 and PGF2 NIUA and NECD 21
Tryptase Acute phase of IgE-mediated 
reactions
229,239
Skin tests Immediate and nonimmediate 
reactions to drugs
231





Immediate reactions to 
betalactams






Granzyme B and 
granulysin
Stevens–Johnson syndrome 238
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distinct from their lymph nodes (LN) counterpart as they suppress B 
and Tfh cells with a much lower capacity, while circulating memory-like 
Tfh cells are more potent than LN effector Tfh cells.282 In addition, 
circulating memory-like Tfr cells persist for long periods; thus, they 
could support the long-term immunomodulatory effect of peptide AIT. 
Besides the accumulative effects, AIT also activated Treg functions. 
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Treg cells isolated from Dermatophagoides pteronyssinus (DP) AR pa-
tients treated with DP-SCIT for 12 months could suppress the function 
and proliferation of Th2 and Th9 cells, but increased the proportion 
of IL-10-producing cells.283 Functional evaluation of T regulatory cells 
via expression of glycoprotein A repetitions predominant (GARP) and 
special AT-rich sequence binding protein 1 (SATB1) is also interesting 
as a future potential biomarker. Tregs uniquely express GARP on their 
cell surface, and GARP functions as a delivery system for latent TGF-β, 
which might augment the immunosuppressive role of Tregs on effec-
tor cells.284 GARP expression was described as an activation marker 
of parasitic infection-induced Tregs that strongly suppress allergic in-
flammation; thus, it is a novel potential mechanistic pathway for AIT. 
SATB1 is a genome organizer protein expressed in a lineage-specific 
manner in CD4 + T-cells. During the early Th2 cell differentiation, IL-5 
expression is repressed through direct binding of SATB1 to the IL-5 
promoter. Thus, SATB1 modulation might expand the impact of AIT 
on eosinophilic inflammation. In addition, SATB1-dependent Treg-cell-
specific super-enhancers activation is crucial for Treg cell lineage spec-
ification in the thymus.
11.3 | Basophil activation test
Blood basophils express high levels of FcεRI that have bound IgE. 
To determine sensitization, basophils are incubated in vitro with al-
lergen, followed by examination of degranulation. Fusion of gran-
ules to the cell membrane leads to upregulation of surface markers 
CD63 and CD203c, which are indicative of specific IgE functional 
activity. In patients with AR undergoing SLIT, basophil activation 
decreased with clinical efficacy.285 Similar decreases occurred in 
patients undergoing peanut immunotherapy.271 However, in grass 
pollen SLIT, basophil activation did not correlate with clinical effi-
cacy (Table 3).286
11.4 | Soluble cytokines
With immunotherapy, there is redirection of Th2 phenotype toward 
a Th1 and Treg phenotype with decreases in Th2 cytokines (eg, IL-4, 
IL-19 13, IL-9) and upregulation of Th1 (eg, IFNγ) and regulatory cy-
tokines (eg, TGFβ and IL-10).193,298 However, serum cytokine meas-
urements are challenging due to low levels, which are often below 
the detection limit of current methods.267 Changes in cytokine pro-
duction by CD4 T cells following AIT are assessable through in vitro 
stimulation of PBMC from patients using allergen extracts, at both 
the protein and the transcript levels. In T-cell of patients with HDM 
allergy, high levels of IL10 transcripts predicted immunotherapy 
success.299
11.5 | Epigenetic biomarkers
Beyond cells, proteins and transcripts, epigenetic biomarkers may 
suggest prognosis.300,301 DNA methylation of promoter regions 
is associated with gene silencing, and FOXP3 gene expression is 
in part controlled through this. FoxP3 is the master regulator of 
Treg cells, and Syed et al found that peanut OIT resulted in hypo-
methylation of FOXP3, indicating increased gene expression with 
immunotherapy.302
In conclusion, technological advances inform novel methods 
for monitoring immune responses with increased sensitivity and 
specificity. Studies indicate dysregulation of a number of molecular 
F I G U R E  8   Current view on mechanism and biomarkers in use to monitor AIT. A, Scheme of immune modulation by AIT, where low-dose, 
repeated exposure to allergen is thought to occur with limited to no inflammation. As a result, Th skewing is balanced toward Th1 and Treg, 
which subsequently modify the B-cell response. In particular, the production of IL-10 is thought to drive IgG4 class switching. Thus, local 
and systemic memory is rebalanced, in both the T-cell and the B-cell compartments, and there is a strong increase in allergen-specific IgG4 
antibodies. Upon allergen challenge, IgG4 and potentially other soluble factors are thought to inhibit IgE-mediated degranulation of target 
cells, i.e, desensitization. Together with the loss of Th2 skewing, this underlies the observed clinical tolerance. B, Laboratory biomarkers 
utilized in diagnostics and clinical trials for AIT (adapted from267). Abbreviations: IgE-FAB, IgE-facilitated allergen binding; IgE-BF, IgE-
blocking factor; BHR, basophil histamine release; DAO, diamine oxidase; Treg, regulatory T cell; Breg, regulatory B-cell; DC, dendritic cell. 
Figure reproduced from265 
TA B L E  3   Identification of changes in immune cells associated with allergic sensitization
Immune cell type Biomarkers Assay References
Basophils Decrease in basophil activation post-allergen-specific OIT (CD63, 
CD203, histamine release)
BAT, iBAT 287–289
B cells Induction of Breg cells on AIT, serological readouts: food, and allergen-
specific IgE, IgG4 epitope-specific IgE and IgG4
Flow cytometry, ImmunoCAP, 
epitope mapping
182,271,280,290
T cells Functional changes in tetramer positive/CFSElo/CD69 + CD40L+ 
allergen-specific CD4 + T-cells, tracking Th2A cells Decrease in T-cell-
derived Type 2 cytokines Epigenetic changes in T-cell subsets (Tregs)




Dendritic cells Changes in costimulatory potential (CD80, CD86) Flow cytometry, DC-T cell 
co-culture
297,302
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markers with AIT. Detection method optimization continues and 
should facilitate precision immunotherapy.
12  | BIOMARKERS OF THE EPITHELIAL 
BARRIER
Environmental factors, microbiome, epithelial cells and immune 
cells show a dynamic cross talk at the skin and mucosal barri-
ers in the development of AD, AR, CRS, eosinophilic esophagi-
tis and asthma.174,303–308 Studies on the pathogenesis of these 
diseases have clearly demonstrated a barrier defect in the 
skin and involved mucosas and a systemic inflammation.307–310 
Defects in the epithelial barriers, caused by both environmen-
tal risk factors and a genetic predisposition, may represent the 
starting point of a chronic inflammation and allergen sensitiza-
tion.307–310 A significant number of studies have reported that 
environmental factors directly affect the barrier function of 
epithelium.162,311,312 In addition, T helper 2 cells, ILC2s and their 
cytokine IL-13 damage skin and lung barriers.307,313 In addition, 
mast cells and their enzyme chymase damage the epithelial bar-
rier.304,314 The effects of environmental factors may, at least in 
part, be mediated by epigenetic mechanisms. Histone deacety-
lase activation by Type 2 immune response has a major effect on 
leaky barriers, and blocking of histone deacetylase activity cor-
rects the defective barrier in human air–liquid interface cultures 
and mouse models of allergic asthma with rhinitis.107,307,315 The 
assessment of the barrier function of the skin and mucosas in 
vivo has an extremely high value in the clinics to identify barrier 
leakiness for an individual patient and requires the discovery of 
biomarkers.
To date, there are a few noninvasive methods to assess the 
skin epidermal barrier function in vivo. The quantification of 
transepidermal water loss (TEWL) in the skin across the stra-
tum corneum has received some interest for early prediction of 
atopy prone children and detection of skin barrier.316 Although 
TEWL increases in proportion to the level of damage, it is also 
affected by environmental factors such as humidity, tempera-
ture, season and moisture content of the skin.317 The noninvasive 
and rapid measurement of natural moisturizing factor by Raman 
spectroscopy provides a method suitable for use in children. The 
association of natural moisturizing factor, filaggrin null mutations 
and AD suggests Raman spectroscopy as a promising approach 
for stratification of endotypes in AD in the clinics. Other nonin-
vasive methods currently used include assessment of the stratum 
corneum hydration, colorimetry, skin surface pH and sebometry, 
but they only provide information on different characteristics 
and/or the condition of the skin and do not directly measure the 
barrier function.318
Recently, electrical impedance spectroscopy (EIS) has been 
identified as an effective and stable tool for the detection of epi-
dermal barrier.175 This method works by transmitting a harmless 
electrical signal through the skin at several depths and frequencies 
and measuring the electrical resistance and impedance response 
of the tissue. EIS reflects particularly the tissue barrier status by 
collecting the electric impedance information from extracellular 
and intracellular tissue.319 Recently, Rinaldi et al have studied the 
impairment of the epidermal barrier in mice by the epicutaneous 
administration of barrier-damaging proteases, such as papain, tryp-
sin, Vibrio cholera toxin or by tape stripping.175 They showed the 
barrier-damaging effects of these substances which correlate with 
the electric conductivity of the skin, causing a decrease in electri-
cal impedance. According to these results, EIS shows a broad range 
of possible clinical applications in AD and atopic march, including 
early prediction of atopy-prone children, early diagnosis of the dis-
ease, stratification and endotyping of patients, evaluation of the 
overall therapy response as well as single lesions and assessment 
of disease severity.
A critical feature of the gastrointestinal epithelium is intestinal 
barrier permeability as it must allow an efficient passage of nutrients 
while restricting the entry of larger molecules to avoid food allergy 
development. Multiple autoimmune diseases have been identified to 
arise or be exacerbated by a leaky gut, such as in inflammatory bowel 
disease, celiac disease, Type 1 diabetes, systemic lupus erythemato-
sus, multiple sclerosis.320–323 Recent studies point to a leaky gut as 
the initiator of Type 1 diabetes because a subclinical intestinal bar-
rier dysfunction was already detected before clinical onset of Type 
1 diabetes.324 Zonulin is a prehaptoglobulin protein and a biomarker 
for gut barrier leakiness that downregulates TJ function, and it has 
been proposed to play a role in several autoimmune diseases.325
Translocation of bacterial endotoxin (lipopolysaccharide, LPS) 
from the gut microbiota to blood circulation stimulates systemic in-
flammatory responses.326 Measurement of intestinal permeability is 
often used in the examination of inflammatory gastrointestinal dis-
orders. It can be assessed by measurement of urinary recovery of 
ingested nonmetabolizable lactulose and mannitol. Urine L/M ratio 
measured by1 H NMR spectroscopy showed high correlation with 
the standard measurement of the urinary recoveries by enzymatic 
assays. In conclusion, NMR metabolomics enables simultaneous in-
testinal permeability testing and discovery of biomarkers associated 
with an impaired intestinal permeability.327 In conclusion, identifica-
tion of clinically reliable biomarkers for skin, respiratory and intestinal 
barrier measurements represents an important future research area.
The value of barrier detection in allergic diseases
• Early prediction of atopic dermatitis development in 
babies
• Patient selection for certain therapies, endotyping and 
personalized medicine
• Early prediction and monitoring response to treatments
• Early and rapid analyses of environmental hazards to 
skin and mucosas before severe lesions start
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13  | IN VIVO BIOMARKERS IN AIT 
DE VELOPMENT PROGR AMS: EUROPE AN 
IMPLIC ATIONS
An increasing number of clinical trials in AIT have been published 
underlining both efficacy and safety of AIT as the only disease-mod-
ifying treatment option for patients with IgE-mediated respiratory 
allergic diseases.328 With country-specific exceptions, AIT prod-
ucts are regulated by authorities such as the European Medicines 
Agency329 and others on the basis of methodological guidelines.
In its guideline “Clinical Development of Products for Specific 
Immunotherapy for The Treatment of Allergic Diseases”,329 the 
European regulatory authority (European Medicine Agency (EMA)) 
has provided strict guidance for designing and performing clinical 
development programs in AIT.113,330 In Germany, these principles 
were followed in the “Therapy Allergen Ordinance (TAV)“ for future 
registration of allergens and allergen mixtures (derived from grass 
pollen, early flowering trees pollen, house dust mites, and bee and 
wasp venom) based on the main prevalent respiratory allergies in 
Germany.331–333 First registrations have been granted fulfilling the 
TAV demands by the German Paul Ehrlich Institut (PEI).334 Besides, 
a sufficient body of evidence exists in the clinical documentation of 
both SLIT and SCIT AIT products.335–337
An important unmet need for further harmonization of meth-
odological principles in AIT study design338 has been followed in a 
series of Task-Force initiatives of the European Academy of Allergy 
and Clinical Immunology (EAACI)339 as overviewed in the 2019 
report of our group.113 As such, position papers and guidelines on 
allergen-challenge procedures including clear standardization of 
procedures (SOPs) through the nasal340 or conjunctival341 route 
have been provided by the EAACI. As aforementioned, the safety, 
reproducibility and cutoff points for NAC have also been proven 
recently.96,97
In addition, the combined symptom and medication score (CSMS) 
as defined by the EAACI as standard primary endpoint for future 
(pivotal) trials in AIT342 has been recently used recently in an increas-
ing number of key trials in AIT.343–345 However, further formal vali-
dation and amendments especially for the pediatric population are 
needed.334,346 As another example, a further Task Force initiative 
aimed to provide clear clinically and aerobiologically justified defi-
nitions of pollen counts for onset, peak and duration of pollen sea-
sons347 and they have been confirmed to be robust348 and clinically 
relevant as reflecting patients’ symptom load in different countries 
in Europe in recent reports.348,349 Recently, the EAACI has published 
a Position Paper reporting the impact of the placebo effect in AIT 
from different methodological perspectives and outlining possible 
strategies to minimize this bias in clinical trials.350
Taken together, further emphasis should be put on international 
collaborations of clinical experts, methodologists and regulatory au-
thorities to optimize methodological standards for AIT clinical devel-
opment programs aimed to increase the level of evidence of AIT as 
the only disease-modifying therapy available.334,337,351
14  | BIOMARKERS ON THE CLINIC AL 
USAGE OF BIOLOGIC AL S IN THE E A ACI
The EAACI recently published the Guidelines on the use of biologi-
cals in severe asthma. Recommendations were formulated follow-
ing the GRADE approach352–354 for each biological (benralizumab, 
dupilumab, mepolizumab, omalizumab, reslizumab) and each out-
come (decrease in asthma exacerbations, oral and inhaled corticos-
teroids and rescue medication use; improvement in asthma control, 
quality of life and lung function; and safety).33 The recommendations 
were informed by three systematic reviews.355–357 FeNO, sputum 
and blood eosinophils were scored as outcomes with low impor-
tance; however, the evidence was analyzed for subgroups based on 
biomarkers and comorbidities. The higher the blood eosinophils, the 
higher the expected impact of benralizumab, dupilumab and mepoli-
zumab in reducing severe asthma exacerbations. The improvement 
in asthma control was significantly better in the high-eosinophil 
subgroup for benralizumab and reslizumab. Lung function increased 
significantly more in the high eosinophil subgroup for benralizumab, 
dupilumab and reslizumab. Benralizumab improved QoL better in the 
high-eosinophil subgroup. The effect of omalizumab on exacerba-
tions did not depend on blood eosinophils. Neither the atopic status 
nor total IgE predicts the magnitude of effect of benralizumab, and 
serum IgE thresholds (within regulatory limits) did not influence the 
response to omalizumab (Table 4).
In addition, biomarkers were used to characterize the population 
where a strong recommendation is made instead of a conditional 
one, for example for dupilumab in improving lung function for asth-
matic and adolescent adults with blood eosinophils > 300 cells/μL 
and/or with FeNO levels > 50 ppb. This upgrade was possible as 
in this subgroup the addition of dupilumab to standard of care im-
proved FEV1 above the minimal important difference threshold.
The Guideline Development Group (GDG) formulated a three-pil-
lar decision tree aiming to help the clinician in reaching the decision 
to start on a particular biological based on the combination between 
phenotypic traits, biomarkers (blood and sputum eosinophils, FeNO) 
and clinically relevant asthma-related endpoints. For suboptimal re-
sponse, the GDG recommends to re-assess airway inflammation and 
airway hyperresponsiveness (conditional recommendation, expert 
opinion based). Induced sputum is the preferred option to re-assess 
airway inflammation (conditional recommendation, expert opinion 
based) as a noninvasive validated tool. The GDG strongly recom-
mends joint efforts from academia, industry and healthcare systems 
to develop both educational tools and resources supporting a wider 
use of induced sputum evaluation in severe asthma. If at re-evalu-
ation for suboptimal response there is no airway eosinophilia and 
neutrophilic inflammation is present, the biological should be inter-
rupted and measures addressing non-T2 asthma such as macrolides 
should be considered (conditional recommendation, expert opinion 
based). In cases with no airway inflammation, addressing airway 
hyperresponsiveness (LABA/LAMA combinations or bifunctional 
drugs) or airway remodeling (bronchial thermoplasty in selected 
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cases) is recommended (conditional recommendation, expert opin-
ion based).
Identification of clinically relevant biomarkers in order to select 
responders to the currently available biologicals was identified as 
high priority, and proof-of-concept prospective studies evaluating 
patient selection based on biomarkers were proposed as a tool to 
overcome this barrier in severe asthma research.
Another recently published EAACI Guideline formulated recom-
mendations for the use of AIT with HDM for HDM-driven allergic 
asthma. To date, there are no biomarkers that sufficiently predict 
response to HDM-AIT that can be used to decide on initiation or 
cessation of HDM AIT in HDM-driven allergic asthma.358
15  | CONCLUSIONS
In our discipline, a huge amount of omics research has been em-
ployed during recent years that needs to be analyzed in depth. 
Allergic diseases are a group of complex and heterogeneous dis-
eases. Specific, sensitive and reliable (point-of-care) biomarkers are 
critical for selecting the proper treatment for the proper patient and 
enabling precision medicine. Precision endotyping is linking patho-
biological mechanisms with visible properties via specific biomark-
ers. It is expected to be translated into pathway-specific diagnostic 
tests and opens a pathway to accurate disease classification and in-
dividualized targeted treatment options. We are expecting to change 
the diagnostic and therapeutic landscape in our specialty as well as 
of all medical disciplines. However, endotype-driven treatment still 
needs to face multiple challenges before its implementation in daily 
practice in allergic diseases and asthma. Most of the disease endo-
typing research is conducted in severe forms of allergic diseases 
nowadays. Over the past few years, the biomarker discovery field 
has gained great advances, which facilitates the identification of 
novel methods for disease diagnosis and therapy. With these fast 
growing efforts, we can imagine that in the near future, we will be 
able to find better ways to treat allergic diseases, with a therapeutic 
approach targeted to the individual patient.
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Decrease in severe asthma 
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The higher the blood eosinophils, the higher the 
expected impact
Conditional recommendation
Omalizumab Decrease in severe asthma 
exacerbations
The effect does not depend on blood eosinophils Conditional recommendation
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expected impact
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Clinically significant effect in asthmatic 
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Improvement in lung 
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The higher the blood eosinophils, the higher the 
expected impact
Conditional recommendation
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